Park Ha Biological Technology Co., Ltd. BYAH
Company Overview
Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. It operates in two segments, Product Sales and Franchise Service. The company offers various products, such as basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance, and anti-aging under the Park Ha brand. It sells products to customers through directly operated retail stores, and franchisees. The company has a strategic partnership with Star Plus Action (HK) Limited to build an AI-powered skincare and health ecosystem and expand its healthcare reach. Park Ha Biological Technology Co., Ltd. has strategic partnership with Cloud Factory Technology Holdings Limited to build ai-driven ecosystem for the beauty industry. The company was founded in 2016 and is headquartered in Wuxi, the People's Republic of China. Park Ha Biological Technology Co., Ltd. operates as a subsidiary of Xiaoqiu Holding Ltd.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Oct 2025 Revenue of $2.52M (+6.0% YoY); net profit $-24.36M.
- Trailing 12 Months Year-on-year growth — revenue +1.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.6%, profit CAGR -4278.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.57% |
| 1 Year: | 1.50% |
Compounded Profit Growth
| 5 Years: | -4,278.85% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -99.01% |
| 6 Months: | -79.67% |
| 3 Months: | -88.49% |
| 1 Month: | -22.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)34.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -4278.8% CAGR over 5 years.
- Trading 99.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BYAH Park Ha Biological Technology Co., Ltd. | 2.44 | -0.06 | $1.82M | 0.00% | - | -113.04% | 9.57% | -4,278.85% |
| 2 | WMT Walmart Inc. SPXR3K | 107.14 | 38.82 | $850.02B | 0.93% | 16.83% | 22.31% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 910.18 | 45.88 | $403.65B | 0.65% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 88.36 | 26.53 | $380.17B | 2.41% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 145.58 | 21.99 | $338.39B | 2.95% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 184.73 | 25.37 | $287.92B | 3.09% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 138.45 | 18.15 | $189.12B | 4.43% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 79.73 | 17.18 | $139.30B | 1.69% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | BTI British American Tobacco p.l.c. | 55.15 | 14.18 | $118.73B | 5.98% | 12.44% | 13.42% | -2.53% | 5.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.92M | 2.46M | 2.38M | 2.52M |
| Cost of Revenue | - | 509.16K | 310.99K | 195.34K | 142.53K |
| Gross Profit | - | 1.41M | 2.15M | 2.19M | 2.38M |
| Operating Expenses | - | 1.21M | 967.56K | 1.39M | 26.53M |
| Operating Income | - | 197.02K | 1.18M | 793.71K | -24.15M |
| EBITDA | - | 220.69K | 1.20M | 816.11K | -23.97M |
| Interest Expense | - | 194 | 0 | 0 | 41 |
| Pretax Income | - | 190.01K | 1.18M | 793.42K | -24.08M |
| Tax Provision | - | -1.29K | 329.53K | 314.86K | 280.65K |
| Net Income | - | 191.30K | 852.04K | 478.56K | -24.36M |
| Diluted EPS | -0.93 | 0.37 | 1.63 | 0.91 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 2.52M | 2.26M | 3.08M | 5.95M |
| Current Assets | - | 2.26M | 2.18M | 2.84M | 5.50M |
| Cash & Equivalents | - | 574.71K | 1.03M | 547.50K | 3.79M |
| Inventory | - | 94.17K | 95.87K | 71.49K | 75.21K |
| Receivables | - | 119.21K | 361.74K | 330.89K | 255.84K |
| Total Liabilities | - | 2.37M | 1.25M | 1.58M | 1.96M |
| Current Liabilities | - | 2.37M | 1.24M | 1.52M | 1.88M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 26.19K | 31.46K | 70.32K | 180.17K |
| Total Equity | - | 150.28K | 1.01M | 1.51M | 3.99M |
| Shares Outstanding | - | 524.00K | 524.00K | 524.00K | 677.49K |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 1.44M | 126.54K | 960.47K | 85.85K |
| Investing Cash Flow | - | -1.55M | 1.02M | -508.14K | -572.93K |
| Financing Cash Flow | - | 669.65K | -676.92K | -957.39K | 3.74M |
| Capital Expenditure | - | -11.89K | -22.68K | -85.57K | -88.83K |
| Free Cash Flow | - | 1.43M | 103.86K | 874.90K | -2.97K |
| Net Change in Cash | - | 564.35K | 473.03K | -505.06K | 3.25M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 73.5% | 87.4% | 91.8% | 94.4% |
| Operating Margin % | - | 10.3% | 48.0% | 33.3% | -956.5% |
| Net Margin % | - | 10.0% | 34.6% | 20.1% | -965.0% |
| ROE % | - | 127.3% | 84.2% | 31.8% | -609.9% |
| ROCE % | - | 131.1% | 115.5% | 50.9% | -593.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Virtu Financial LLC | 0.15% | 3.56K | $8.57K |
| 2 | Morgan Stanley | 0.14% | 3.13K | $7.54K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BYAH
BYAH Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE9EY1h2a2owbzZaS0FLcU5WckJLN0ItRG5ZdGpsNVUzVHdKWmRSV2pDZUNuTjJObzNuRmxYM2QwVWJ0c3NJVVRoQkJPb0llSnNGMml0S3pySXp5TFlvMWc?oc=5" target="_blank">BYAH Should I Buy</a> <font c…
BYAH Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Lawsuit Against Park Ha Biological Technology Co, Ltd - TMX Newsfile
<a href="https://news.google.com/rss/articles/CBMilwJBVV95cUxPZFZWRVp0aS1MUmpmSFJRNzF5aEp1cm0zdGVfaHVYZXlKZF9qLXBCOEtGMERDVkxwc1gwZ2tiQmRXVmFlYTZzTlcxYW9fdnZxQ1luQU1yTW1ZN3V5c2lqVDNGTzgwMDNDSjJzeHBfOUR6RTBYeThWQXE5SUY5aUFWUEh1SEJiRmFpblprcW…
BYAH Investor Alert: Park Ha Biological Technology Co., Ltd. Securities Class Action Notice - Contact SueWallSt - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxQdVpyTUF0S0szU252eVl4ODk2ZFA0TXlJRmEtZlBvMW1fdm50aHpHYURCdXViMGRqY1phMkRKdTI0Zm1JVG12eXpEV1V2elVnRDBmMGtjdE5zbDVtQXkzNlhzX1JjTHpHRUlDaFRmZl9aMGVaUWJtM3dnZmZuaVgzQmIwelZMR0hKeWh5Mm…
Levi & Korsinsky Reminds Park Ha Biological Technology Co. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026 - BYAH - Morningstar
<a href="https://news.google.com/rss/articles/CBMiwAJBVV95cUxPalB5X3AyMmJJVDdWVTJac1htWkpMb2tiVWM3QUxGT2lXdFFuWmVic0NUdEgyaC0zSC1DOGN6R0hqUkh1T0dDYkpxclk1Y1hGenpNMmVkNVdUYXFJYzhndDRVaXlkZ08xZmcxUlV1ajEzRk1iWndlRExIdkxYRzV6UjRhNmF2RHhEa1FRc0…
Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTFBTWGF3MDBIYUxXN2JudEJsbTZBc1RPdkYwcHlMd19RWWpRVkV1RklTZVV1ZUZNV1dUeGRhQ1I0WUl6RjAweEptQXhPay1TcUNrQmlKQXhR?oc=5" target="_blank">Park Ha Biological Technology Co., Ltd. (NASDAQ: BY…
BYAH Shareholder Alert: Park Ha Biological Technology Co., Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky - Business Wire
<a href="https://news.google.com/rss/articles/CBMiqAJBVV95cUxNSXJSb2JUTGhWdmJZQ2Z1SEpvcng5YUlsRTFmVVRNZzlHS25oNFNYMDByMlMtd1htaGdZb2hTRDZYNnpKeVMyU2FxQXBXOEpoZjlWZDJVOXJKS3kycENTSVNJbUdfSHR4QkducG43WVZCeWZYUUpiT2lwVU9BbVpYRklDVEJ4YmRfSHk4YX…
BYAH — Frequently Asked Questions
What is the current share price of Park Ha Biological Technology Co., Ltd. (BYAH)?
As of 2026-09-19 21:16 PDT, Park Ha Biological Technology Co., Ltd. (BYAH) trades at $2.44 on NasdaqCM. Its 52-week range is $2.44 to $246.00.
What is the market capitalisation of BYAH?
Park Ha Biological Technology Co., Ltd. (BYAH) has a market capitalisation of $1.82M on NasdaqCM.
What is the P/E ratio of BYAH?
BYAH trades at a trailing price-to-earnings (P/E) ratio of -0.06. The industry average P/E is 18.56. Its price-to-book (P/B) ratio is 0.28.
What is the return on equity (ROE) of BYAH?
BYAH has a return on equity (ROE) of -113.04%.
Is BYAH a good stock to buy?
This page provides a data-driven analysis of Park Ha Biological Technology Co., Ltd. (BYAH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.